Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Autor:	Mena-Vázquez N; Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Malaga, Spain.; UGC de Reumatología, Hospital Regional Universitario de Málaga, 29009 Malaga, Spain., Rojas-Gimenez M; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14004 Cordova, Spain.; UGC de Reumatología, Hospital Universitario Reina Sofía de Córdoba, 14004 Cordova, Spain., Fuego-Varela C; UGC de Reumatología, Hospital Universitario de Jerez, 11407 Cadiz, Spain., García-Studer A; Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Malaga, Spain.; UGC de Reumatología, Hospital Regional Universitario de Málaga, 29009 Malaga, Spain., Perez-Gómez N; UGC de Reumatología, Complejo Hospitalario Universitario de Vigo, 36214 Vigo, Spain., Romero-Barco CM; Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Malaga, Spain.; UGC de Reumatología, Hospital Clínico Universitario Virgen de la Victoria, 29010 Malaga, Spain., Godoy-Navarrete FJ; UGC de Reumatología, Hospital Universitario de Jaén, 23007 Jaen, Spain., Manrique-Arija S; Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Malaga, Spain.; UGC de Reumatología, Hospital Regional Universitario de Málaga, 29009 Malaga, Spain.; Departamento de Medicina, Universidad de Málaga, 29010 Malaga, Spain., Gandía-Martínez M; UGC de Reumatología, Hospital Universitario de Jerez, 11407 Cadiz, Spain., Calvo-Gutiérrez J; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14004 Cordova, Spain.; UGC de Reumatología, Hospital Universitario Reina Sofía de Córdoba, 14004 Cordova, Spain., Morales-Garrido P; UGC de Reumatología, Hospital Universitario Clínico San Cecilio, 18016 Granada, Spain., Mouriño-Rodriguez C; UGC de Reumatología, Complejo Hospitalario Universitario de Vigo, 36214 Vigo, Spain., Castro-Pérez P; UGC de Reumatología, Hospital Universitario de Getafe, 28901 Madrid, Spain., Añón-Oñate I; UGC de Reumatología, Hospital Universitario de Jaén, 23007 Jaen, Spain., Espildora F; UGC de Neumología, Hospital Regional Universitario de Málaga, 29009 Malaga, Spain., Aguilar-Hurtado MC; UGC de Radiodiagnóstico, Hospital Regional Universitario de Málaga, 29009 Malaga, Spain., Hidalgo Conde A; Servicio de Medicina Interna, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain., Arnedo Díez de Los Ríos R; Servicio de Medicina Interna, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain., Cabrera César E; UGC Neumología, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain., Redondo-Rodriguez R; Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Malaga, Spain.; UGC de Reumatología, Hospital Regional Universitario de Málaga, 29009 Malaga, Spain., Velloso-Feijoo ML; UGC de Reumatología, Hospital Universitario Virgen de Valme, 41014 Sevilla, Spain., Fernández-Nebro A; Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Malaga, Spain.; UGC de Reumatología, Hospital Regional Universitario de Málaga, 29009 Malaga, Spain.; Departamento de Medicina, Universidad de Málaga, 29010 Malaga, Spain.
Jazyk:	angličtina
Zdroj:	Biomedicines [Biomedicines] 2022 Jun 22; Vol. 10 (7). Date of Electronic Publication: 2022 Jun 22.
DOI:	10.3390/biomedicines10071480
Abstrakt:	Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Methods: We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. Results: The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2-42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03-3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70-0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72-0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Conclusion: Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu